It would also seem relevant to study the expression of other oncoproteins associated indirectly with proliferation (c-erbB-2), which is frequently associated with poorer prognosis in a range of solid tumours; and also with oncoproteins associated with the induction (p53) and inhibition (bcI-2) of the apoptotic process. bcI-2 inhibits most kinds of programmed cell death, providing selective survival advantage to various cell types. Whilst it has been seen to be normally expressed in ductal epithelia of the breast, overexpression was correlated with ER and PGR receptor expression in breast tumours, and was inversely correlated with Ki67 antibody binding (proliferation), and c-erbB-2, but not correlated with c erbB-1 (EGFr). bcI-2 expression was generally associated with favourable histopathological features, whilst loss of bcI-2 was linked to loss of hormonal regulation, increased de-differentiation and deregulated proliferation. 5 However, it is not clear whether the findings reported for beast cancer are also true for uveal melanoma.
Melanoma evades the immune system in part by downregulating HLA Class I antigens on the cell surface, which are reqUired for T-cell recognition. The oncogene c-myc may have a role in effecting this change in vitro, although the relationship between oncoprotein level and tumour antigenicity has not been established in human tumours. In a study of 94 skin melanoma lesions (46 primary, 46 regional metastases) using flow cytometry, Grover et al. 6 measured Class I expression (using immunohistochemistry) and c-myc expression (using flow cytometry). c-myc expression was found on 91 tumours (96%), with higher expression in metastatic compared with primary lesions. Class I expression was highly variable, with generally lower expression than primary tumours. Both parameters showed significant correlation between primary and metastatic disease, high oncoprotein being associated with down-regulation of cell surface antigens. In a further flow cytometric studl uveal melanoma tumours and cell lines expressing MHC Class I were found to be insensitive to NK-cell-mediated lysis, in vivo and in vitro. Disruption of NK cell function increased the hepatic metastases.
Heymann et al. B reported that ICAM-1 cell-cell adhesion is essential for different immunological functions including non-MHC-restricted cytotoxicity. The shedding of soluble ICAM-1 is thought to impair immune recognition and lead to tumour escape. HILDA/ LIF or OSM increased ICAM-1 expression 2-fold but not sICAM-I. Tumour necrosis factor-alpha stimulated both forms. ICAM-1 upregulation was concomitant with an increase in non-MHC-restricted cytotoxicity of tumour cells mediated by LAK cells, and abolished by an anti ICAM-1 antibody.
Clearly there is considerable value in measuring protein expression for a range of biological markers, if the data thus generated will enable a better understanding of the complex interaction of tumour proliferation and apoptotic pathways, and of host/ tumour immunology as well as tumour invasiveness. We now present the application of this technique to a group of 63 samples taken from 59 uveal melanoma tumours.
Multiple samples from the same patient occurred when melanotic and amelanotic lesions were clearly identifiable in the enucleated eye. Cells were isolated from these tumour samples, fixed and then stained with a panel of monoclonal antibodies selected to reflect four key mechanisms that cells within a tumour may need for disease progression: proteins involved in cell proliferation (c-myc, c-erbB-2), cell death mechanisms (p53, bcI-2), the host immune response (HLA-DR, W632) and tumour cell adhesion or migration (ICAM-1). Tissue samples were, however, variable in size, and hence cell yield. Not all samples were therefore applied to the whole antibody panel. Furthermore, the results presented for p53 represent only a pilot study on 18 samples.
Materials and methods

Patient group
Fresh tumour tissue was collected following enucleation, transported in liquid nitrogen to the laboratory, and then either stored, or dissociated to produce a single cell suspension. Patient details and clinical information were recorded in a database. Pathological analysis was undertaken by an ophthalmic pathologist.
Tissue preparation
Samples of primary ocular melanoma collected following enucleation were divided for storage, histological examination or immediate use. Single-cell suspensions were generated by dicing pieces of fresh tissue with scalpels in phosphate-buffered saline (PBS) containing antibiotics. Cells for flow cytometric analysis were washed in PBS, fixed in 1% paraformaldehyde at room temperature for 5 min with frequent mixing, washed in PBS and permeabilised in 70% methanol cooled to 4°C, for a further 15 min period at room temperature, then stored at 4 0c.
Flow cytometric staining.
Cell suspensions were washed in PBS then PBS containing 1% fetal calf serum (PBS/serum), 0.5 X 10 6 cells aliquoted into tubes, and the primary (test) antibody added at an appropriate concentration (typically 5 or 10 I.Ll neat antibody). Staining was carried out for 30 min at 4°C, followed by washing in PBS/serum. The second stage fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse antibody (goat anti-mouse F(ab' )2, Caltag) was then added (100 I.Ll at 1/100 dilution in PBS/serum) for a further 30 min at 4°C (protected from light). The samples were then washed in PBS/serum to remove excess antibody, and the pellet resuspended. The DNA fluorochrome, propidium iodide (PI, Sigma, Dorset, UK) was then added (300 fLl at 50 fLg/ml in PBS) for at least 30 min (protected from light), together with 50 fLl RNAse (5 U / mt, Sigma, Dorset, UK), after which samples were syringed (25 G needle) and filtered through a 50 fLm stainless steel mesh to remove any large aggregates of cells before analysis on the flow cytometer. The quality of DNA staining (peak CV) was improved by overnight storage at 4°C in the final buffer containing PI DNA dye and RNAse.
Monoclonal antibodies assessed
The following panel of antibodies were used: Negative control: FITC second-stage goat anti-mouse f(ab')2 antibody (Caltag). Positive control: PHM-5 epithelial! endothelial antibody (Silenus, Bio-Stat Diagnostics, Stockport, UK). W632 MHC Class I antibody (a generous gift from the BTS Labs., Sheffield, UK). HLA-DR MHC Class II antibody CR3/43 (DAKO, High Wycombe, UK). ICAM-1 (CD54) adhesion molecule antibody (a generous gift from ICRF, London). C-erbB-2 cytoplasmic domain antibody, code OM11952 (CRB, Cheshire, UK). c-myc (against peptide mid-region) antibody 6E10 (CRB, Cheshire, UK). bC/-2 antibody 124 (DAKO, High Wycombe, UK). p53 antibody DO-7 wild-type and mutant protein (DAKO, High Wycombe, UK).
Flow cytometry
Samples were routinely analysed on a FACSort bench top flow cytometer (Becton Dickinson, Oxford, UK). Doublet discrimination was applied to exclude cell clumps using peak height and width analysis of the DNA fluorescence parameter. Ten thousand cells were routinely analysed for their DNA content, cell cycle and monoclonal antibody staining characteristics (% positive cells and mean fluorescence industry). Antibody (FITC)
fluorescence was recorded using a 530 nm band pass filter, and DNA dye fluorescence (PI) using a 620 nm long pass filter. Stored files were analysed for DNA ploidy and % S-phase cells by the Modfit DNA software analysis package (Verity Software House, USA). Samples where the diploid GO/G 1 peak had a coefficient of variation (cv) greater than 10 were excluded from the present study, and retested if possible. The study group cv range was 3.3-8.9, median 6.4.
Data analysis
Flow cytometric data was measured as median channels of fluorescence for DNA peak positions (linear fluorescence scales), and calculated mean fluorescent channels (log fluorescent scales) for antibody staining. Flow cytometric data were correlated with the clinical findings using a non-parametric Mann-Whitney U-t-test statistical package, and Spearman correlation coefficients calculated for percentage staining data generated by the antibody panel used (two-tailed significance). patients, but the maximum follow-up period was only 8 years and may therefore be too short. Oncoprotein antibody expression was significantly associated with cell type. c-erbB-2 was found in greater amounts in spindle cell tumours than in mixed/ epitheloid tumours (median 71%, range 20-97, n = 19 versus median 48%, range 5-93, n = 27) (p = 0.023). The median percentage c-erbB-2 positivity for the whole group was 61 %, n = 46. c-myc was also expressed more by spindle cell tumours: the total sample group gave a median 24% cells (range 3-93, n = 13), whilst spindle cell 
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Me1215 p53/DNA Whilst Class I expression was not found to show statistical significance between the groups analysed (pathology, tumour volume, DNA ploidy and the presence or absence of metastases), Class II expression was found to be statistically higher in spindle cell tumours compared with mixed/ epitheloid cell tumours (p = 0.04). This may suggest that the improved prognosis associated with spindle cell tumours may be linked to MHC expression and the ability initiate an immune response against tumour cells, thereby preventing metastatic dissemination.
No statistical correlation was identified between DNA content (34 diploid, 24 aneuploid) and any of the clinicopathological parameters measured; nor with the calculated S-phase fraction. There was no statistical correlation between the S-phase fraction and the presence or absence of metastases, yet correlations did exist between % S-phase cells and the percentage of cells labelling with c-erhB-2 and c-myc antibodies (p = 0.003 and 0.03 respectively). Table 2 Results shown include the sample group size (n), median (m) data value of the group (data being % cells positive for the antibody after background subtraction from controls) and the significance value (p). Significant results are shown in bold.
aThe p53 data represent a pilot study and are based on only a low number of samples.
respectively). We were unable to detect correlations with metastases, possible due to the fact that we can present only an 8 year follow-up. When measuring DNA ploidy by flow cytometry, it is a simple task also to define the S-phase fraction as an index of proliferation. In the present study there was no correlation between the S-phase fraction and DNA ploidy; nor between S-phase, cell type or survival. Previous reports have similarly concluded that there are no significant correlations between the calculated S-phase fraction and prognosis. 9 -11 Whilst the S-phase fraction can be used as a direct means of quantifying cellular proliferation, there are other recognised ways of identifying whether a cell is undergoing cell cycle or not. For example, the Ki67 antibody recognising a histone epitope only exposed during DNA replication is frequently used. In one such study of 79 uveal melanomas I2 S-phase correlated with Ki67 but not PCNA, the proliferating cell nuclear antigen.
peNA is one of the family of cell-cycle-specific proteins or cyclins, expressed at specific phases of the cell cycle and, under normal circumstances, rapidly degraded when the cell no longer requires them. Ki67 correlated with histopathological type and tumour size (Ki67 stained epitheloid cell type and large tumours) and also correlated with reduced survival. However, ploidy did not correlate with either the Ki67 or PCNA antigens.
Many oncoproteins have been identified as having either stimulatory of inhibitory roles in cell cycle progression. They may take the form of growth factor receptors such as the c-erbB-2 oncoprotein. This protein is one member of the epidermal growth factor receptor (EGFr) and transforming growth factor receptor (TGFr) family. These growth factors may exert either a stimulatory or an inhibitory effect on cell growth, respectively. In a study of 80 melanoma patients, van Dam et al. 13 detected overexpression of IGFr-l (11 %), EGFr (12%), c-erbB-2 (24%), c-ras (20%) and c-myc (35%), with levels of expression of IGFr, EGFr, c-erbB-2 and c-ras being higher in patients with recurrent disease. Diffuse c-erbB-2 positivity and p53 overexpression may both be associated with advanced dysplasia. 14 Eccles et al. 15 reported that c-erbB-l (EGFr) and c-erbB-2 expression is closely linked to poor prognosis and an invasive / metastatic phenotype, and relative insensitivity to conventional therapies. Overexpression of c-erbB-2 is thought to be an early event in breast cancer; has been found to be more frequent in aneuploid tumours than diploid tumours; is correlated with increasing S-phase and ER negativity; and fluorescence intensity (level of expression) was correlated with prognosis. 16 Our study also showed a correlation with S-phase (p = 0.003), and h igh levels of expression in the majority of the sample group, suggesting that c-erbB-2 may also be an early event in uveal melanoma.
Oncoproteins may have a role in cell cycle signalling. For example, the c-myc protein is implicated in both growth promotion and growth arrest depending upon th e environment the cell is exposed to, and whether signals favour cell death or cell survival. Royds et al. 4 investigated c-myc oncoprotein expression in 24 ocular melanoma samples using immunofluorescence, staining with the 6ElO mid-portion, and 9EI0 C-terminus antibodies. Staining with c-myc antibodies was found to be indicative of proliferation, with correlations noted between total c-myc staining and the proliferative index. Our results also support this finding, with a correlation between % S-phase cells and % c-myc positivity (p = 0.003).
The p53 gene product functions as a tumour suppressor gene, being responsible for inducing either growth arrest or cell death through the process of apoptosis once DNA damage has been identified. The presence of wild-type p53 expression is therefore an indication of growth control, whilst mutant protein or a total lack of protein would indicate the lack of inhibitory growth control, and the possible survival of cells bearing DNA damage or mutations which would otherwise be killed by apoptosis. p53 was used only as a pilot study in the present report. However, preliminary results correlated p53 and bcl-2 expression (p = 0.023) and ICAM-l expression (p = 0.008) but did not show any correlation between levels of p53 antibody binding and the clinical and pathological parameters used. It is also too soon to suggest whether this marker may be of value in determining a patient's response to therapy. Ryan et al. 17 assessed whether c-myc and bcl-2 were able to modulate p53 function by altering p53 subcellular trafficking during the cell cycle, and reported that coincident expression of p53 and bcl-l in murine cell lines prolonged survival. Furthermore, co-expression of bcl-2 and c-myc was found to totally overcome p53-induced apoptosis and cell cycle arrest. This was thought to be by altering subcellular trafficking of p53 remaining in the cytoplasm at Gv instead of moving to the nucleus during this phase of the cell cycle. The bcl-2 gene product is a major protein in the apoptotic pathway serving to save cells from programmed cell death by inhibiting further signals in the pathway. The level of bcl-2 in the present study was high in almost all samples measured, and was found to correlate with p53 in the pilot study (p = 0.023). However, p53 was not associated with particular cell types, tumour origin or tumour size. This suggests that bcl-2 expression may be an early event in uveal melanoma, and high expression of this protein may make it a candidate target for developing therapies.
Tumour survival must be considered to be a balance between the cellular response to survival or death signals, and the nature and extent of the host immune response. Tumour cell expression of major histocompatibility complexes (MHC) may be the most significant factor in deciding whether the host can mount a cytotoxic or natural killer response to the tumour. The protocol used in the present study enabled the use of antibodies against the MHC Class I and Class II determinants, and therefore the correlation of levels of staining with clinicopathological parameters. Our results showed MHC Class II to be a potentially significant factor, with reduced expression in the more aggressive mixed / epitheloid tumours and, theoretically, a reduced ability to activate an immune response. This was not noted with MHC Class I and is in agreement with a study of 41 melanomas in which an average of 85% cells stained with HLA AlBIC compared with only 7% staining for HLA-DR. 18 It is of interest to note that there may be a biological association between c-myc and MHC molecule expression. Grover et al. 6 studied 94 skin melanoma samples (46 primary, 48 regional metastases), and found 96% to be c-myc positive, with higher expression in the metastatic samples. More importantly, c-myc expression correlated with down-regulation of both MHC Class I and Class II surface antigens -a result also found in the present study (Class II vs c-myc, p = 0.03; Class I vs c-myc, p = 0.15).
Cell-cell contact for many cell types is a prerequisite for survival, so the expression of interce11ular adhesion molecules (ICAMs) may be considered to be an important property of tumour cells. However, our data indicate that the larger the tumour, and therefore the more likely it is to contain cells of metastatic phenotype, the greater is the expression of the ICAM-l (CD54) protein. This would seem to support the view that, in this case, ICAM-l expression may be a requirement for cell mobility or migration, and thus be a marker of the presence of metastatic cells in uveal melanoma. In summary, we present data from a large group of uveal melanoma patients whose tumours have been dissociated, fixed and permeabilised, and stained with a monoclonal antibody and DNA fluorochrome. These multiparameter data have been correlated with a range of clinical and pathological criteria, and four have been identified as being of potential significance in the diagnosis, prognosis and management of this disease, namely: ICAM-I, MHC Class II, and the oncoproteins c myc and c-erb-b2. Our aim will be to follow these patients over a longer time period to assess which of the tested parameters may have a predictive value for the onset of metastatic disease.
